Literature DB >> 23478961

Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.

Kevin A Brown1, Nagham Khanafer, Nick Daneman, David N Fisman.   

Abstract

The rising incidence of Clostridium difficile infection (CDI) could be reduced by lowering exposure to high-risk antibiotics. The objective of this study was to determine the association between antibiotic class and the risk of CDI in the community setting. The EMBASE and PubMed databases were queried without restriction to time period or language. Comparative observational studies and randomized controlled trials (RCTs) considering the impact of exposure to antibiotics on CDI risk among nonhospitalized populations were considered. We estimated pooled odds ratios (OR) for antibiotic classes using random-effect meta-analysis. Our search criteria identified 465 articles, of which 7 met inclusion criteria; all were observational studies. Five studies considered antibiotic risk relative to no antibiotic exposure: clindamycin (OR = 16.80; 95% confidence interval [95% CI], 7.48 to 37.76), fluoroquinolones (OR = 5.50; 95% CI, 4.26 to 7.11), and cephalosporins, monobactams, and carbapenems (CMCs) (OR = 5.68; 95% CI, 2.12 to 15.23) had the largest effects, while macrolides (OR = 2.65; 95% CI, 1.92 to 3.64), sulfonamides and trimethoprim (OR = 1.81; 95% CI, 1.34 to 2.43), and penicillins (OR = 2.71; 95% CI, 1.75 to 4.21) had lower associations with CDI. We noted no effect of tetracyclines on CDI risk (OR = 0.92; 95% CI, 0.61 to 1.40). In the community setting, there is substantial variation in the risk of CDI associated with different antimicrobial classes. Avoidance of high-risk antibiotics (such as clindamycin, CMCs, and fluoroquinolones) in favor of lower-risk antibiotics (such as penicillins, macrolides, and tetracyclines) may help reduce the incidence of CDI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23478961      PMCID: PMC3632900          DOI: 10.1128/AAC.02176-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  On logit confidence intervals for the odds ratio with small samples.

Authors:  A Agresti
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 3.  Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.

Authors:  Claudia Thomas; Mark Stevenson; Thomas V Riley
Journal:  J Antimicrob Chemother       Date:  2003-05-13       Impact factor: 5.790

4.  Community Clostridium difficile.

Authors:  Jayakeerthi Rangaiah; Mark Wilks; Michael Millar
Journal:  BMJ       Date:  2009-06-03

5.  Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting.

Authors:  D G Levy; A Stergachis; L V McFarland; K Van Vorst; D J Graham; E S Johnson; B J Park; D Shatin; J C Clouse; G W Elmer
Journal:  Clin Ther       Date:  2000-01       Impact factor: 3.393

6.  Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection.

Authors:  Vanessa Stevens; Ghinwa Dumyati; Lynn S Fine; Susan G Fisher; Edwin van Wijngaarden
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

7.  A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors.

Authors:  Susanna Naggie; Becky A Miller; Kimberly B Zuzak; Brian W Pence; Ashley J Mayo; Bradly P Nicholson; Preeta K Kutty; L Clifford McDonald; Christopher W Woods
Journal:  Am J Med       Date:  2011-03       Impact factor: 4.965

8.  Clinical and microbiological characteristics of community-onset Clostridium difficile infection in The Netherlands.

Authors:  M P Bauer; D Veenendaal; L Verhoef; P Bloembergen; J T van Dissel; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2009-07-16       Impact factor: 8.067

9.  Characterisation and carriage ratio of Clostridium difficile strains isolated from a community-dwelling elderly population in the United Kingdom.

Authors:  Fabio Miyajima; Paul Roberts; Andrew Swale; Valerie Price; Maureen Jones; Michael Horan; Nicholas Beeching; Jonathan Brazier; Christopher Parry; Neil Pendleton; Munir Pirmohamed
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

10.  Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study.

Authors:  Jennifer L Kuntz; Elizabeth A Chrischilles; Jane F Pendergast; Loreen A Herwaldt; Philip M Polgreen
Journal:  BMC Infect Dis       Date:  2011-07-15       Impact factor: 3.090

View more
  152 in total

Review 1.  Minority report: the intestinal mycobiota in systemic infections.

Authors:  Thierry Rolling; Tobias M Hohl; Bing Zhai
Journal:  Curr Opin Microbiol       Date:  2020-06-27       Impact factor: 7.934

2.  Are there reasons to prefer tetracyclines to macrolides in older patients with community-acquired pneumonia?

Authors:  S Di Bella; F Taglietti; N Petrosillo
Journal:  Antimicrob Agents Chemother       Date:  2013-08       Impact factor: 5.191

3.  Clostridioides difficile-Associated Antibiotics Alter Human Mucosal Barrier Functions by Microbiome-Independent Mechanisms.

Authors:  Jemila C Kester; Douglas K Brubaker; Jason Velazquez; Charles Wright; Douglas A Lauffenburger; Linda G Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiaries.

Authors:  Courtney E Collins; M Didem Ayturk; Julie M Flahive; Timothy A Emhoff; Frederick A Anderson; Heena P Santry
Journal:  J Am Coll Surg       Date:  2014-02-28       Impact factor: 6.113

5.  Second generation cephalosporin antibiotic prophylaxis and Clostridium difficile infection in hip and knee arthroplasty.

Authors:  K Al-Tawil; A Babu; M Loeffler; T Williams
Journal:  Ann R Coll Surg Engl       Date:  2017-05       Impact factor: 1.891

6.  Is Clostridium difficile the new bugaboo after cardiac surgery?

Authors:  Simona Silvetti; Giovanni Landoni
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

7.  Characteristics and Antibiotic Use Associated With Short-Term Risk of Clostridium difficile Infection Among Hospitalized Patients.

Authors:  Sol del Mar Aldrete; Matthew J Magee; Rachel J Friedman-Moraco; Austin W Chan; Grier G Banks; Eileen M Burd; Colleen S Kraft
Journal:  Am J Clin Pathol       Date:  2015-06       Impact factor: 2.493

8.  Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study.

Authors:  Kevin Antoine Brown; Bradley Langford; Kevin L Schwartz; Christina Diong; Gary Garber; Nick Daneman
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

9.  Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.

Authors:  B Kullin; J Wojno; V Abratt; S J Reid
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-30       Impact factor: 3.267

10.  Is the penetration of clindamycin into the masseter muscle really enough to treat odontogenic infections?

Authors:  Paula I Faggion; Gabriela Isoton; Eduarda Possa; Leandro Tasso
Journal:  Clin Oral Investig       Date:  2020-10-31       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.